Viking Therapeutics, Inc. Operating Income
Viking Therapeutics, Inc. (VKTX) reported Operating Income of -$132.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-29
- Viking Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$132.60M.
- Viking Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$164.13M.
- Viking Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$164.74M.
- Viking Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$98.56M.
- Viking Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$393.34M.
- Viking Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$150.92M.
- Viking Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$100.83M.
- Viking Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$70.36M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$132.60M 10-Q · filed 2026-07-29 | -$296.72M 10-Q · filed 2026-07-29 | -$461.46M derived: sum of 3 quarters · filed 2026-07-29 | -$560.02M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | -$164.13M 10-Q · filed 2026-04-30 | -$328.86M derived: sum of 2 quarters · filed 2026-04-30 | -$427.42M derived: sum of 3 quarters · filed 2026-04-30 | -$502.00M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | -$164.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$263.30M derived: sum of 2 quarters · filed 2026-02-11 | -$337.87M derived: sum of 3 quarters · filed 2026-07-29 | -$393.34M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | -$98.56M 10-Q · filed 2025-10-23 | -$173.13M derived: sum of 2 quarters · filed 2026-07-29 | -$228.60M 10-Q · filed 2025-10-23 | -$274.84M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | -$74.57M 10-Q · filed 2026-07-29 | -$130.04M 10-Q · filed 2026-07-29 | -$176.28M derived: sum of 3 quarters · filed 2026-07-29 | -$212.84M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | -$55.47M 10-Q · filed 2026-04-30 | -$101.71M derived: sum of 2 quarters · filed 2026-04-30 | -$138.26M derived: sum of 3 quarters · filed 2026-04-30 | -$172.32M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | -$46.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$82.79M derived: sum of 2 quarters · filed 2026-02-11 | -$116.85M derived: sum of 3 quarters · filed 2026-02-11 | -$150.92M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | -$36.56M 10-Q · filed 2025-10-23 | -$70.61M derived: sum of 2 quarters · filed 2025-10-23 | -$104.68M 10-Q · filed 2025-10-23 | -$133.97M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | -$34.05M 10-Q · filed 2025-07-23 | -$68.13M 10-Q · filed 2025-07-23 | -$97.41M derived: sum of 3 quarters · filed 2026-02-11 | -$124.68M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | -$34.07M 10-Q · filed 2025-04-24 | -$63.36M derived: sum of 2 quarters · filed 2026-02-11 | -$90.62M derived: sum of 3 quarters · filed 2026-02-11 | -$114.36M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | -$29.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$56.55M derived: sum of 2 quarters · filed 2026-02-11 | -$80.29M derived: sum of 3 quarters · filed 2026-02-11 | -$100.83M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | -$27.27M 10-Q · filed 2024-10-23 | -$51.01M derived: sum of 2 quarters · filed 2024-10-23 | -$71.54M 10-Q · filed 2024-10-23 | -$91.83M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | -$23.74M 10-Q · filed 2024-07-24 | -$44.28M 10-Q · filed 2024-07-24 | -$64.56M derived: sum of 3 quarters · filed 2025-02-26 | -$80.76M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | -$20.54M 10-Q · filed 2024-04-25 | -$40.82M derived: sum of 2 quarters · filed 2025-02-26 | -$57.02M derived: sum of 3 quarters · filed 2025-02-26 | -$74.65M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | -$20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$36.48M derived: sum of 2 quarters · filed 2025-02-26 | -$54.11M derived: sum of 3 quarters · filed 2025-02-26 | -$70.36M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | -$16.20M 10-Q · filed 2023-10-25 | -$33.83M derived: sum of 2 quarters · filed 2023-10-25 | -$50.07M 10-Q · filed 2023-10-25 | -$62.58M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-06-30 | -$17.63M 10-Q · filed 2023-07-26 | -$33.88M 10-Q · filed 2023-07-26 | -$46.39M derived: sum of 3 quarters · filed 2024-02-07 | -$59.79M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-03-31 | -$16.25M 10-Q · filed 2023-04-26 | -$28.75M derived: sum of 2 quarters · filed 2024-02-07 | -$42.16M derived: sum of 3 quarters · filed 2024-02-07 | -$57.70M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2021-12-31 | -$12.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | -$25.91M derived: sum of 2 quarters · filed 2024-02-07 | -$41.45M derived: sum of 3 quarters · filed 2024-02-07 | -$55.68M 10-K · filed 2024-02-07 | ||||
| 2021-09-30 | -$13.40M 10-Q · filed 2022-10-26 | -$28.94M derived: sum of 2 quarters · filed 2022-10-26 | -$43.17M 10-Q · filed 2022-10-26 | -$54.44M derived: sum of 4 quarters · filed 2022-10-26 | ||||
| 2021-06-30 | -$15.54M 10-Q · filed 2022-07-27 | -$29.77M 10-Q · filed 2022-07-27 | -$41.03M derived: sum of 3 quarters · filed 2022-07-27 | -$50.88M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | -$14.23M 10-Q · filed 2022-04-27 | -$25.49M derived: sum of 2 quarters · filed 2022-04-27 | -$35.34M derived: sum of 3 quarters · filed 2022-04-27 | -$45.94M derived: sum of 4 quarters · filed 2022-04-27 | ||||
| 2020-12-31 | -$11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$21.11M derived: sum of 2 quarters · filed 2022-02-09 | -$31.71M derived: sum of 3 quarters · filed 2022-02-09 | -$42.66M 10-K · filed 2022-02-09 | ||||
| 2020-09-30 | -$9.84M 10-Q · filed 2021-11-03 | -$20.45M derived: sum of 2 quarters · filed 2021-11-03 | -$31.40M 10-Q · filed 2021-11-03 | -$40.27M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | -$10.61M 10-Q · filed 2021-07-28 | -$21.55M 10-Q · filed 2021-07-28 | -$30.43M derived: sum of 3 quarters · filed 2021-07-28 | -$37.87M derived: sum of 4 quarters · filed 2021-07-28 | ||||
| 2020-03-31 | -$10.95M 10-Q · filed 2021-04-28 | -$19.82M derived: sum of 2 quarters · filed 2021-04-28 | -$27.26M derived: sum of 3 quarters · filed 2021-04-28 | -$36.83M derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | -$8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$16.31M derived: sum of 2 quarters · filed 2021-02-17 | -$25.88M derived: sum of 3 quarters · filed 2021-02-17 | -$32.69M 10-K · filed 2021-02-17 | ||||
| 2019-09-30 | -$7.44M 10-Q · filed 2020-10-28 | -$17.01M derived: sum of 2 quarters · filed 2020-10-28 | -$23.81M 10-Q · filed 2020-10-28 | -$30.85M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | -$9.57M 10-Q · filed 2020-07-29 | -$16.38M 10-Q · filed 2020-07-29 | -$23.41M derived: sum of 3 quarters · filed 2020-07-29 | -$30.81M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | -$6.81M 10-Q · filed 2020-04-30 | -$13.84M derived: sum of 2 quarters · filed 2020-04-30 | -$21.24M derived: sum of 3 quarters · filed 2020-04-30 | -$28.16M derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-12-31 | -$7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$14.43M derived: sum of 2 quarters · filed 2020-02-26 | -$21.36M derived: sum of 3 quarters · filed 2020-02-26 | -$26.16M 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | -$7.39M 10-Q · filed 2019-11-05 | -$14.32M derived: sum of 2 quarters · filed 2019-11-05 | -$19.12M 10-Q · filed 2019-11-05 | -$23.55M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | -$6.92M 10-Q · filed 2019-08-01 | -$11.73M 10-Q · filed 2019-08-01 | -$16.16M derived: sum of 3 quarters · filed 2019-08-01 | -$20.85M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | -$4.80M 10-Q · filed 2019-05-02 | -$9.23M derived: sum of 2 quarters · filed 2019-05-02 | -$13.92M derived: sum of 3 quarters · filed 2019-05-02 | -$18.91M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$9.12M derived: sum of 2 quarters · filed 2019-03-13 | -$14.10M derived: sum of 3 quarters · filed 2019-03-13 | -$19.07M 10-K · filed 2019-03-13 | -$19.07M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | -$4.69M 10-Q · filed 2018-11-07 | -$4.69M 10-Q · filed 2017-11-08 | -$9.68M derived: sum of 2 quarters · filed 2018-11-07 | -$14.64M 10-Q · filed 2018-11-07 | -$14.64M 10-Q · filed 2017-11-08 | -$18.38M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | -$4.98M 10-Q · filed 2018-08-09 | -$4.98M 10-Q · filed 2017-08-09 | -$9.95M 10-Q · filed 2018-08-09 | -$9.95M 10-Q · filed 2017-08-09 | -$13.69M derived: sum of 3 quarters · filed 2018-08-09 | -$16.95M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | -$4.97M 10-Q · filed 2018-05-09 | -$4.97M 10-Q · filed 2017-05-10 | -$8.71M derived: sum of 2 quarters · filed 2018-05-09 | -$11.97M derived: sum of 3 quarters · filed 2018-05-09 | -$15.55M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$7.00M derived: sum of 2 quarters · filed 2018-03-07 | -$10.58M derived: sum of 3 quarters · filed 2018-03-07 | -$13.85M 10-K · filed 2018-03-07 | ||||
| 2016-09-30 | -$3.26M 10-Q · filed 2017-11-08 | -$6.84M derived: sum of 2 quarters · filed 2017-11-08 | -$10.11M 10-Q · filed 2017-11-08 | -$14.73M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | -$3.58M 10-Q · filed 2017-08-09 | -$6.85M 10-Q · filed 2017-08-09 | -$11.47M derived: sum of 3 quarters · filed 2017-08-09 | -$15.75M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | -$3.27M 10-Q · filed 2017-05-10 | -$7.89M derived: sum of 2 quarters · filed 2017-05-10 | -$12.18M derived: sum of 3 quarters · filed 2017-05-10 | -$14.80M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | -$4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | -$8.91M derived: sum of 2 quarters · filed 2017-03-21 | -$11.54M derived: sum of 3 quarters · filed 2017-03-21 | -$12.00M 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | -$4.29M 10-Q · filed 2016-11-10 | -$6.92M derived: sum of 2 quarters · filed 2016-11-10 | -$7.38M 10-Q · filed 2016-11-10 | -$7.73M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | -$2.63M 10-Q · filed 2016-08-11 | -$3.09M 10-Q · filed 2016-08-11 | -$3.44M derived: sum of 3 quarters · filed 2016-08-11 | -$4.59M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | -$461.04K 10-Q · filed 2016-05-10 | -$814.61K derived: sum of 2 quarters · filed 2016-05-10 | -$1.96M derived: sum of 3 quarters · filed 2016-05-10 | -$23.72M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | -$353.56K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$1.50M derived: sum of 2 quarters · filed 2016-03-08 | -$23.26M derived: sum of 3 quarters · filed 2016-03-08 | -$23.47M 10-K · filed 2016-03-08 | ||||
| 2014-09-30 | -$1.15M 10-Q · filed 2015-11-05 | -$22.90M derived: sum of 2 quarters · filed 2015-11-05 | -$23.11M 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | -$21.76M 10-Q · filed 2015-08-14 | -$21.97M 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | -$209.74K 10-Q · filed 2015-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |